Legislation Roe v. Wade State Legislation Supreme Court State Laws Reproductive Rights Public Opinion Ballot Measures Democratic Party Ohio Women's Health Ballot Initiatives State Constitutional Amendments Supreme Court Decisions Republican Party Supreme Court Rulings Constitutional Amendments Mifepristone Legal Challenges Protests Anti-Abortion Groups FDA Approval State Constitution State Constitutions Reproductive Health Abortion Ballot Measures Medication Abortion Supreme Court Ruling Pro-Life Movement Judicial Decisions Abortion Bans State Bans Presidential Candidates Abortion Access Republican Stance Women's Rights Lawsuits Anti-Abortion Movement State Elections Joe Biden Legislative Control Federal Law State Referendums Legislative Actions State Restrictions Texas Advocacy Elections Anti-Abortion Advocates State-Level Bans Access to Medication Abortion Conservative Opposition Dobbs Decision Healthcare Policy Federal Ban FDA Regulations Michigan Republican Candidates Pro-life Movement U.S. Supreme Court Texas Abortion Ban Abortion Restrictions President Biden Donald Trump Virginia Kentucky 2024 Presidential Election State Constitution Amendments FDA Approval of Mifepristone Opposition Restrictions on Abortion Supreme Court Decision Reproductive Freedom Ohio Ballot Measure Advocacy Groups Ohio Constitutional Amendment 2024 Elections Referendums State Amendments Legal Issues Abortion Pill State Protections Republican Presidential Candidates State Politics State Supreme Court Vice President Kamala Harris Federal Funding National Abortion Ban State Legislatures Roe v. Wade Reversal Endorsements Legal Disputes Protection for Providers Legal Actions Voter Enthusiasm State Supreme Court Decisions Consensus Measures Presidential Actions National vs. Local Issue Politics & Elections
Marty Makary states mifepristone access will remain unchanged unless future safety data signals an issue.